Isomorphic Labs’ $2.1 Billion Fundraise Is The Biggest Bet Yet On AI Drug Discovery
The funding will expand Isomorphic Labs’ AI drug design engine and support hiring as it pushes therapeutic programs toward clinical trials.
- On Tuesday, Alphabet-founded Isomorphic Labs announced a $2.1 billion Series B financing led by Thrive Capital, marking the largest venture funding for a biotech company since at least 2022.
- Founded in 2021 as a spin-off of Google DeepMind, the company utilizes its proprietary Isomorphic Labs Drug Design Engine, which builds upon the AlphaFold AI model that predicts protein structures.
- Isomorphic President Max Jaderberg said the company aims to "redefine the way we create new medicines," supported by partnerships with Novartis, Eli Lilly, and Johnson & Johnson worth up to $3 billion combined.
- The new funding will support deployment of the AI drug design engine and accelerate hiring, with Isomorphic targeting its first clinical trials by the end of 2026.
- CEO Demis Hassabis told Bloomberg News that a full spinoff from Alphabet is "definitely" possible, though Isomorphic remains an Alphabet subsidiary amid intensifying competition in AI-designed drug discovery.
11 Articles
11 Articles
AI Drug Designer Isomorphic Details Lofty Plans for $2.1B in New Funding
Alphabet subsidiary Isomorphic Labs, eyeing the crown in the nascent AI-designed drugs sector, announced Tuesday that it raised $2.1 billion. Now, it just has to make good on the whole promise of completely revolutionizing the pharmaceutical industry. No pressure. Aye, AI, Sir Isomorphic was founded in 2021 as a spinout of Google DeepMind, the research laboratory responsible for developing the search giant’s AI tools, including Gemini. The CEO a…
DeepMind CEO Demis Hassabis’ Isomorphic Labs raises $2.1 billion led by Thrive Capital
AI-driven drug discovery firm Isomorphic Labs secured a massive $2.1 billion in Series B funding. This capital will fuel the expansion of their AI drug design engine and advance therapeutic candidates. The investment underscores strong confidence in their innovative approach to tackling diseases.
DeepMind spinout Isomorphic Labs closes $2.1B from Thrive Capital, GV, Alphabet for AI drug discovery
Isomorphic Labs has secured $2.1 billion in Series B funding led by Thrive Capital, with backing from Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund. The London-based company plans to use the fresh capital to expand its AI drug design engine, accelerate therapeutic programs into clinical stages, and hire top scientific and engineering talent globally. Isomorphic Labs could become one of Europe’s most valuable biotech and AI…
Coverage Details
Bias Distribution
- 80% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
